Spending just 15 minutes in nature can have this surprising health benefit
For millions of people across the country living in busy urban environments, finding a touch of nature can be challenging. But data from a team at Stanford University in California shows it could be worth the effort, particularly for young adults.
The study, published in the journal Nature Cities, reported 'significant benefits' of spending even a short time in nature for a broad range of mental health conditions, saying the data showed a 'mental health solution'.
More than 80 per cent of the UK population lives in urban areas, government statistics show, with the number expected to continue to grow.
Analysis of close to 5,900 participants found they didn't need to be active to feel an improvement, with stationary time in green spaces found to be more effective at reducing negative mental health outcomes like depression than active time in nature.
They found all types of urban nature provided benefits, but urban forests were the best for reducing depression and anxiety.
Young adults experienced even greater benefits than the general population, researchers said, which they added was 'important' because 'most mental health disorders emerge before the age of 25'.
The team hopes to help advise urban planners and decision-makers in cities, using models to predict how increased green spaces could help prevent mental health disorders and bring down healthcare costs, as well as bringing 'additional benefits' like lowering temperatures and sequestering carbon.
'For example, we could run scenarios like: if a city currently has 20 per cent green space or tree cover, how many preventable cases of mental health disorders could be avoided if that were increased to 30 per cent?' said lead author Lingjie Li. ' We will also be working to include estimates of the potential avoided healthcare costs associated with such improvements in urban nature.'
They added that while larger city parks and forests are 'critical', urban planners should also consider including 'pocket parks' and planting more trees on streets to help bring the benefits of nature into dense urban areas.
Dr Li said doing the work has improved his own lifestyle, adding that he now walks to the office more frequently and finds he is more curious about birds and plants he encounters along the way.
'I also talk to my friends about thinking this way and encourage them to notice how even small moments with nature can make a difference,' he said. 'This work has helped me see that urban nature isn't just good for cities – it's good for us.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst
Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly's recent setback and expand treatment options beyond injections. The study, which began in January 2025, will assess the safety, tolerability, pharmacokinetics and weight-loss efficacy of once-daily oral dosing over a 13-week period. VK2375 is being developed in oral and subcutaneous formulations. The target population consists of adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid study's primary endpoint is the percent change in body weight from baseline after 13 weeks of treatment. Secondary and exploratory endpoints will evaluate additional safety and efficacy measures. Viking expects to release results in the second half of 2025, with William Blair projecting an August readout. Analyst Andy Hsieh wrote Tuesday, 'Our base-case expectation is to replicate the 4-week Phase I results, translating to a placebo-adjusted weight loss of slightly under 7% for the highest doses.' Hsieh highlighted the advantage of using the same active ingredient across oral and injectable formats, allowing patients to switch between the two without increasing the risk of new side effects. William Blair reiterated its Outperform rating on Viking shares. Given the underwhelming weight loss magnitude from Eli Lilly and Co.'s (NYSE:LLY) Phase 3 ATTAIN-1 trial of orforglipron, coupled with potential uncertainties associated with the persistent rate of adverse events, the analyst believes the setback creates a clinical void for smaller competitors to fill. 'We expect Viking to rise to the occasion and demonstrate the potential of the oral tablet formulation of VK2735 as a competitive option in the maintenance setting. We therefore would be buyers before the Phase II VENTURE-oral readout,' William Blair wrote in an investor note on Tuesday. In June, Viking Therapeutics initiated the VANQUISH Phase 3 clinical program for subcutaneous VK2735. In 2024, Viking announced topline results from the Phase 2 VENTURE study of subcutaneous VK2735 in obesity. Patients receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7%, and statistically significant reductions in mean body weight relative to placebo, ranging up to 13.1%. Price Action: VKTX stock is trading higher by 2.38% to $40.81 at last check Wednesday. Read Next:Image via Shutterstock Latest Ratings for VKTX Date Firm Action From To Feb 2022 Raymond James Maintains Outperform Jul 2021 Raymond James Maintains Outperform May 2021 Raymond James Downgrades Strong Buy Outperform View More Analyst Ratings for VKTX View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Gizmodo
25 minutes ago
- Gizmodo
Doctors Were Worse at Spotting Cancer After Leaning on AI, Study Finds
Artificial intelligence tools have been shown to help doctors detect pre-cancerous growths in the colon—but don't even think about taking those tools away once you've introduced them. A new study published this week in The Lancet found that doctors who are given AI tools to assist with identifying potential cancer risks in patients get worse at making those same observations when they go back to doing it without AI's help. The study looked at four endoscopy centers in Poland, tracking the success rates of detecting colon cancer for three months before AI tools were introduced and three months after. Once AI was introduced, colonoscopies were randomly assigned to either receive AI support or not. The researchers found that doctors who gave colonoscopies without AI after having its assistance available saw their detection rates drop, producing outcomes 20% worse than what they were before AI was introduced. Making the results all the more troubling is the fact that the 19 doctors who participated in the study were all very experienced and had performed more than 2,000 colonoscopies each. If those doctors can fall prey to de-skilling, seeing their own abilities erode because of reliance on AI tools, the outcomes from inexperienced doctors could be even worse. There is little doubt that AI tools can help in medical settings. There have been numerous studies that suggest that AI can facilitate everything from the detection of cancers to the diagnosis of illnesses based on a patient's medical history. Analyzing information based on a whole wealth of previous examples is kinda the bread and butter of AI (you know, as opposed to generating braindead content slop), and there is evidence that suggests that humans can augment their own abilities by using AI tools. Studies in medical settings have found that doctors who use these tools can produce better outcomes for their patients. But no one, including doctors, is immune to the risk of shutting your brain off and relying on AI rather than their own skills. Earlier this year, Microsoft published a study that found knowledge workers who lean on AI stop thinking critically about the work they are doing and feel confident that the assistance from AI will be enough to get the job done. Researchers at MIT similarly found that relying on ChatGPT for essay writing resulted in less critical engagement with the material. In the long term, there's a real risk that reliance on AI will erode our ability to problem solve and reason, which is not ideal when AI continues to generate bad information. The American Medical Association found that about two in three physicians have already adopted AI to augment their abilities. Hopefully, they're still able to identify when it does something like hallucinating a body part that doesn't exist.
Gizmodo
25 minutes ago
- Gizmodo
The Bizarre Biological Trick That Makes Mollusk Teeth Tougher Than Steel
At first glance, chitons look like any other mollusk: round, bashful creatures creeping across seashore rocks. Flip one over, however, and you'll notice rows of freakishly sharp, polished teeth—indestructible, multi-purpose chompers that researchers are seeking to replicate for the next breakthrough in material science. A new study published August 7 in Science presents a detailed investigation into what makes chiton teeth so strong and durable. By analyzing chiton anatomy, the team found a remarkably precise, consistent stream of iron-binding proteins that resulted in dental structures 'superior to materials used in industrial cutting tools, grinding media, dental implants, surgical implants, and protective coatings,' paper co-author David Kisalilus explained in a statement. Even more impressive is the fact that, unlike human-made materials, chitons produce their teeth at room temperature with nanoscale precision, he added. The new paper lays out the underlying mechanisms of this process, which the researchers believe could inform future advances in the fabrication of advanced materials. 'We can learn a lot from these biological designs and processes,' said Kisalius, a materials scientist at the University of California. Kisalius collaborated with research partners in Japan to study larger types of chitons found in the northwest United States and the coasts of Hokkaido, Japan. They identified a protein, RTMP1, which is unique to chitons and enables the deposition of iron onto the mollusks' teeth. Scientists knew that this allowed chitons to scrape off stubborn bits of algae from rock, but it was unknown how and when these proteins interacted with chiton teeth. Using tools from both material science and molecular biology, the researchers built the protein's itinerary through chiton anatomy 'from the ground up,' Kisalilus explained. First, RTMP1 travels through nanoscopic tubes leading out from each tooth, then binds to compounds that control the architecture of magnetite, a type of iron oxide. At the same time, the protein releases the iron stored in ferritin, another protein found in the tissues near chiton teeth. As a result, the new teeth grow into neat rows of ultrahard structures that also grow back after a certain amount of wear. The results demonstrate a fantastic opportunity for humans to learn from nature. Further investigations into chiton teeth could inform 'spatially and temporally controlled synthesis of other materials for a broad range of applications, such as batteries, fuel cell catalysts, and semiconductors,' Kisailus said, in addition to 'new approaches toward additive manufacturing—3D printing—and synthesis methods that are far more environmentally friendly and sustainable.' Those are perhaps grand expectations for a creature as visually unassuming as the chiton. Then again, these mollusks look extra metal when flipped over (both literally and figuratively). So who knows? Maybe chiton dental steel will truly be the next big thing in materials science.
